.png){kind=icon}
.png){kind=icon}
Return
Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial
.png){kind=icon}
PRE
AI
T
S
P
C
D
P
P
O
A
P
F
É
C
DOI：10.1016/j.jtha.2026.06.045.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The effect of low-molecular-weight heparin, administered from the time of diagnosis of fetal growth restriction (FGR), on fetal growth and birthweight remains uncertain.
Journal
IF:
5
Papers:
9.8K
Citations:
2.3W
Organization
Cited Papers